Long-Term Safety and Efficacy Outcomes following Conversion-to-Eslicarbazepine Acetate (ESL) Monotherapy in Patients with Partial-Onset Seizures (POS): A Post-Hoc Subgroup Analysis of Patients Who Continued to Receive ESL as Monotherapy for up to 12 Months (P3.242)

Conclusions:Efficacy and safety outcomes for the ‘true ESL monotherapy’ patient subgroup (no AEDs added back during the OLE) were favorable and generally consistent with those for the total OLE population, although with fewer SAEs and discontinuations due to TEAEs.Study Supported by: Sunovion Pharmaceuticals Inc.Disclosure: Dr. Chung has received personal compensation for activities with UCB Pharma, Eisai, Lundbeck, Upsher-Smith, and Sunovion. Dr. Chung has received research support from Lundbeck, UCB Pharma, Upsher-Smith, and SK Life Sciences. Dr. Sinha has received personal compensation for activities with Monteris, Inc., Cyberonics, Inc., and Cadwell as an advisory. Dr. Sinha has received resaerch support from UCB Pharmaceuticals, Cyberonics Inc., Upsher-Smith Labs, Biogen, Inc., and Sage Pharmaceuticals. Dr. Shah has received personal compensation from UCB Pharma and Lundbeck as a speaker. Dr. Stern received personal compensation for activities with UCB Pharma, Sunovion, Lundbeck, and Eisai Inc. as an advisor and/or speaker. Dr. Stern has received personal compensation in an editorial capacity for MedLink Neurology. Dr. Cheng has received personal compensation for activities with Sunovian Pharmaceuticals, Inc. as an employee. Dr. Grinnell has received personal compensation for activities with Sunovion Pharmaceuticals as an employee. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Chung, S., Sinha, S., Shah, A., Stern, J., Cheng, H., Grinnell, T., Blum, D. Tags: Epilepsy and Clinical Neurophysiology: Therapeutics I Source Type: research